Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis

By T. Jafar, P. Stark, Christopher H. Schmid, M. Landa, G. Maschio, P. D. de Jong, D. de Zeeuw, S. Shahinfar, R. Toto, A. Levey. Annals of Internal Medicine, 2003

1,185 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/dc987babbbfcc8252df8c00012a4cbba2a0ff855

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. S. Laurent
3. E. Schiffrin
4. H. S. Boudier
5. Giuseppe Remuzzi
6. B. K. Pedersen
7. B. Saltin

In Nephrology

1. Marcello Tonelli
2. Giuseppe Remuzzi

Citations in the corpus

• The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. (2011, background): “The benefits of therapy with an angiotensin-converting enzyme inhibitor (ACEI) for slowing progression of established diabetic and nondiabetic CKD are well established.(99,100,144,145) Recent data indicate that, independent of other risk factors (including baseline GFR), more rapid loss of kidney fu”
• ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “Likewise, in a meta-analysis of intervention trials in patients with nondiabetic nephropathy, the progression of CKD correlated with achieved BP, with the slowest progression observed in patients with treated SBP in the range 110–119 mmHg.(532) Unfortunately (see Section 4.”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, methodology): “However, the positive data of the MDRD are strengthened by analyses, admittedly retrospective and observational, of the IDNT trial(425) and of 11 trials in non-diabetic renal patients, showing that systolic blood pressure reduction down to a least 120 mmHg may be beneficial.(426) Finally the dispute”
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, background): “(426) Finally the dispute about the blood pressure goal to preserve renal function in diabetic patients may be futile in view of the evidence available about the benefits of intense blood pressure reduction in these patients, even below 130 mmHg systolic and 80 mmHg diastolic as far as cardiovascula”